Cited by 1,033Alzheimer's disease research and treatmentsAutophagy in Disease and TherapyDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease

Open access

Spilman, Patricia, Podlutskaya, Natalia, Hart, Matthew J., Debnath, Jayanta, Gorostiza, Olivia, Bredesen, Dale, Richardson, Arlan, Strong, Randy, Galvan, Veronica·2010·PLoS ONE

DOI 10.1371/journal.pone.0009979PMC PMC2848616

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Reduced TOR signaling has been shown to significantly increase lifespan in a variety of organisms [1], [2], [3], [4]. It was recently demonstrated that long-term treatment with rapamycin, an inhibitor of the mTOR pathway[5], or ablation of the mTOR target p70S6K[6] extends lifespan in mice, possibly by delaying aging. Whether inhibition of the mTOR pathway would delay or prevent age-associated disease such as AD remained to be determined. METHODOLOGY/PRINCIPAL FINDINGS: We used rapamycin administration and behavioral tools in a mouse model of AD as well as standard biochemical and immunohistochemical measures in brain tissue to provide answers for this question. Here we show that long-term inhibition of mTOR by rapamycin prevented AD-like cognitive deficits and lowered levels of Abeta(42), a major toxic species in AD[7], in the PDAPP transgenic mouse model. These data indicate that inhibition of the mTOR pathway can reduce Abeta(42) levels in vivo and block or delay AD in mice. As expected from the inhibition of mTOR, autophagy was increased in neurons of rapamycin-treated transgenic, but not in non-transgenic, PDAPP mice, suggesting that the reduction in Abeta and the improvement in cognitive function are due in part to increased autophagy, possibly as a response to high levels of Abeta. CONCLUSIONS/SIGNIFICANCE: Our data suggest that inhibition of mTOR by rapamycin, an intervention that extends lifespan in mice, can slow or block AD progression in a transgenic mouse model of the disease. Rapamycin, already used in clinical settings, may be a potentially effective therapeutic agent for the treatment of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0009979

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Developments of a water-maze procedure for studying spatial learning in the rat
Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., & Yoshimori, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5720 · Cited by 6,605
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Self-citation
p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death
Bjørkøy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Øvervatn, A., Stenmark, H., & Johansen, T. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200507002 · Cited by 3,276
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
FoxO3 Controls Autophagy in Skeletal Muscle In Vivo
Mammucari, C., Milan, G., Romanello, V., Masiero, E., Rudolf, R., Del Piccolo, P., Burden, S. J., Di Lisi, R., Sandri, C., Zhao, J., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.001 · Cited by 1,953
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892

Flagged first, then by citations

Show all 52 references

1 of the 52 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 998

Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
The β-Secretase-Derived C-Terminal Fragment of βAPP, C99, But Not Aβ, Is a Key Contributor to Early Intraneuronal Lesions in Triple-Transgenic Mouse Hippocampus
Lauritzen, I., Pardossi-Piquard, R., Bauer, C., Brigham, E., Abraham, J.-D., Ranaldi, S., Fraser, P., St-George-Hyslop, P., Le Thuc, O., Espin, V., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2775-12.2012 · Cited by 201
“Our findings showing the accumulation of C99 in enlarged cathepsin B-positive structures enriched in autofluorescent pigments would be in agreement with the presence of C99 in autophagolysosomal structures and therefore agree with numerous emerging works using mouse AD models, including the 3xTgAD mouse demonstrating…”
BackgroundResult
Regulation of Amyloid Precursor Protein Processing by the Beclin 1 Complex
Jaeger, P. A., Pickford, F., Sun, C.-H. J., Lucin, K. M., Masliah, E., & Wyss‐Coray, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011102 · Cited by 208
Recent Progress in Alzheimer’s Disease Research, Part 3: Diagnosis and Treatment
Hane, F. T., Robinson, M. J., Lee, B. Y., Bai, O., Leonenko, Z., & Albert, M. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160907 · Cited by 211
Inhibition of the Mechanistic Target of Rapamycin (mTOR)–Rapamycin and BeyondPreprint
Lamming, D. W. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025924 · Cited by 205
Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications
Banerjee, R., Beal, M. F., & Thomas, B. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.09.001 · Cited by 199
Neuroprotection Through Rapamycin-Induced Activation of Autophagy and PI3K/Akt1/mTOR/CREB Signaling Against Amyloid-β-Induced Oxidative Stress, Synaptic/Neurotransmission Dysfunction, and Neurodegeneration in Adult Rats
Singh, A. K., Kashyap, M. P., Tripathi, V., Singh, S., Garg, G., & Rizvi, S. I. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0129-3 · Cited by 196
A novel rapamycin analog is highly selective for mTORC1 in vivo
Schreiber, K. H., Arriola Apelo, S. I., Yu, D., Brinkman, J. A., Velarde, M. C., Syed, F. A., Liao, C.-Y., Baar, E. L., Carbajal, K. A., Sherman, D. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11174-0 · Cited by 177
Roles of AMP-activated Protein Kinase in Alzheimer’s Disease
Cai, Z., Yan, L., Li, K., Quazi, S. H., & Zhao, B. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8173-2 · Cited by 198
The role of cellular senescence in ageing of the placenta
Cox, L. S., & Redman, C. (2017) · Placenta · doi:10.1016/j.placenta.2017.01.116 · Cited by 181
The Ubiquitin-Proteasome System and the Autophagic-Lysosomal System in Alzheimer Disease
Ihara, Y., Morishima-Kawashima, M., & Nixon, R. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006361 · Cited by 190
Association Between Autophagy and Neurodegenerative Diseases
Fujikake, N., Shin, M., & Shimizu, S. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00255 · Cited by 197
Amino acid catabolism in Alzheimer’s disease brain: Friend or foe?
Griffin, J. W. D., & Bradshaw, P. C. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/5472792 · Cited by 185
Autophagic and endo-lysosomal dysfunction in neurodegenerative disease
Malik, B. R., Maddison, D. C., Smith, G. A., & Peters, O. M. (2019) · Molecular Brain · doi:10.1186/s13041-019-0504-x · Cited by 187
SQSTM1/p62: a potential target for neurodegenerative disease
Ma, S., Attarwala, I. Y., & Xie, X.-Q. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00516 · Cited by 185
Genetic Reduction of Mammalian Target of Rapamycin Ameliorates Alzheimer's Disease-Like Cognitive and Pathological Deficits by Restoring Hippocampal Gene Expression Signature
Caccamo, A., Pinto, V. D., Messina, A. A., Branca, C., & Oddo, S. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0777-14.2014 · Cited by 186
Autophagy and Neuronal Cell Death in Neurological DisordersPreprint
Nixon, R. A., & Yang, D.-S. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008839 · Cited by 183
Autophagy Activation and Protection From Mitochondrial Dysfunction in Human Chondrocytes
de Figueroa, P. L., Lotz, M., Blanco, F. J., & Caramés, B. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39025 · Cited by 179
Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease
Beauquis, J., Pavía, P., Pomilio, C., Vinuesa, A., Podlutskaya, N., Galvan, V., & Saravia, F. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.09.009 · Cited by 148
Self-citation
Naturally Secreted Amyloid-β Increases Mammalian Target of Rapamycin (mTOR) Activity via a PRAS40-mediated Mechanism
Caccamo, A., Maldonado, M. A., Majumder, S., Medina, D. X., Holbein, W. W., Magrì, A., & Oddo, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.180638 · Cited by 186
Autophagy in the presynaptic compartment in health and disease
Vijayan, V., & Verstreken, P. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201611113 · Cited by 170
Rapamycin and Alzheimer’s disease: Time for a clinical trial?
Kaeberlein, M. R., & Galván, V. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aar4289 · Cited by 171
Clearance of misfolded and aggregated proteins by aggrephagy and implications for aggregation diseases
Hyttinen, J. M. T., Amadio, M., Viiri, J., Pascale, A., Salminen, A., & Kaarniranta, K. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.07.002 · Cited by 172
The Function of Autophagy in Neurodegenerative Diseases
Kiriyama, Y., & Nochi, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125990 · Cited by 178
Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases
Wong, M. (2013) · Biomedical Journal · doi:10.4103/2319-4170.110365 · Cited by 173
A Becn1 mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease
Rocchi, A., Yamamoto, S., Ting, T., Fan, Y., Sadleir, K., Wang, Y., Zhang, W., Huang, S., Levine, B., Vassar, R., et al. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006962 · Cited by 166
Tryptophan metabolism: entering the field of aging and age-related pathologies
van der Goot, A. T., & Nollen, E. A. A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.02.007 · Cited by 166
Targeting Autophagy for the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Liu, J., & Li, L. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00203 · Cited by 162
Calorie restriction mimetics: Can you have your cake and eat it, too?
Ingram, D. K., & Roth, G. S. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.11.005 · Cited by 164
Altered γ-Secretase Processing of APP Disrupts Lysosome and Autophagosome Function in Monogenic Alzheimer’s Disease.
Hung, C. O. Y., & Livesey, F. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.095 · Cited by 159
Alzheimer's disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes
Silva, T., Reis, J., Teixeira, J., & Borges, F. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.03.008 · Cited by 158
Activation of mTOR: a culprit of Alzheimer’s disease?
Cai, Z., Zhou, Y., Xiao, M., Yan, L.-J., & He, W. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75717 · Cited by 161
Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer’s disease
Lin, A., Jahrling, J. B., Zhang, W., DeRosa, N., Bakshi, V., Romero, P., Galván, V., & Richardson, A. G. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x15621575 · Cited by 157
Self-citation
Connecting omics signatures and revealing biological mechanisms with iLINCS
Pilarczyk, M., Fazel‐Najafabadi, M., Kouril, M., Shamsaei, B., Vasiliauskas, J., Niu, W., Mahi, N. A., Zhang, L., Clark, N. A., Ren, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32205-3 · Cited by 154
Rapamycin Activates Autophagy and Improves Myelination in Explant Cultures from Neuropathic Mice
Rangaraju, S., Verrier, J. D., Madorsky, I., Nicks, J., Dunn, W. A., & Notterpek, L. M. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1356-10.2010 · Cited by 153
An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons
Boselli, M. G., Lee, B., Robert, J., Prado, M. A., Min, S., Cheng, C., Silva, M. C., Seong, C., Elsasser, S., Hatle, K. M., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.815126 · Cited by 151
Mammalian Target of Rapamycin: Hitting the Bull′s‐Eye for Neurological Disorders
Chong, Z. Z., Shang, Y., Zhang, L., Wang, S., & Maiese, K. (2010) · Oxidative Medicine and Cellular Longevity · doi:10.4161/oxim.3.6.14787 · Cited by 149
Alzheimer’s disease and type 2 diabetes-related alterations in brain mitochondria, autophagy and synaptic markers
Carvalho, C., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.001 · Cited by 145
p62/SQSTM1 at the interface of aging, autophagy, and disease
Bitto, A., Lerner, C. A., Nacarelli, T., Crowe, E. P., Torres, C. A., & Sell, C. (2014) · AGE · doi:10.1007/s11357-014-9626-3 · Cited by 154
Neuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments
Bartzokis, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.015 · Cited by 142
Targeting autophagy in neurodegenerative diseases
Vidal, R. L., Matus, S., Bargsted, L., & Hetz, C. A. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.002 · Cited by 149
Anti-aging pharmacology: Promises and pitfalls
Vaiserman, A. M., Lushchak, O. V., & Koliada, A. K. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.08.004 · Cited by 148
Autophagy: A new player in skeletal maintenance?
Hocking, L. J., Whitehouse, C., & Helfrich, M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1668 · Cited by 152
Autophagic dysfunction in Alzheimer’s disease: Cellular and molecular mechanistic approaches to halt Alzheimer’s pathogenesis
Uddin, M. S., Mamun, A. A., Labu, Z. K., Hidalgo‐Lanussa, O., Barreto, G. E., & Ashraf, G. M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27588 · Cited by 141
Mitophagy in neurological disorders
Zhang, L., Dai, L., & Li, D. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02334-5 · Cited by 143
Leucine signaling in the pathogenesis of type 2 diabetes and obesity
Melnik, B. C. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i3.38 · Cited by 141
Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer’s disease and vascular cognitive impairment
Skike, C. E. V., Jahrling, J. B., Dorigatti, A. O., Sayre, N. L., Hussong, S. A., Ungvari, Z. I., Lechleiter, J. D., & Galván, V. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00570.2017 · Cited by 144
Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice
Apelo, S. I. A., Pumper, C. P., Baar, E. L., Richardson, N. E., & Lamming, D. W. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glw064 · Cited by 136
Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders
Neasta, J., Hamida, S. B., Yowell, Q. V., Carnicella, S., & Dorit Ron, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005554107 · Cited by 136
Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases
Duarte‐Neves, J., de Almeida, L. P., & Cavadas, C. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.022 · Cited by 144
Mechanical injury suppresses autophagy regulators and pharmacologic activation of autophagy results in chondroprotection
Caramés, B., Taniguchi, N., Seino, D., Blanco, F. J., DʼLima, D. D., & Lotz, M. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33444 · Cited by 138
A toolbox for the longitudinal assessment of healthspan in aging mice
Bellantuono, I., de Cabo, R., Ehninger, D., Di Germanio, C., Lawrie, A., Miller, J., Mitchell, S. J., Navas-Enamorado, I., Potter, P. K., Tchkonia, T., et al. (2020) · Nature Protocols · doi:10.1038/s41596-019-0256-1 · Cited by 145
Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine
Anekonda, T. S., & Quinn, J. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.013 · Cited by 139
Targeting the mTOR Signaling Network for Alzheimer’s Disease Therapy
Wang, C., Yu, J., Miao, D., Wu, Z., Tan, M., & Tan, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8505-8 · Cited by 136
Mammalian target of rapamycin: A valid therapeutic target through the autophagy pathway for alzheimer's disease?
Cai, Z., Zhao, B., Li, K., Zhang, L., Li, C., Quazi, S. H., & Tan, Y. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23011 · Cited by 134
Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL
Shang, Y. C., Chong, Z. Z., Wang, S., & Maiese, K. (2012) · Aging · doi:10.18632/aging.100440 · Cited by 135
Autophagy Dysfunction in Alzheimer’s Disease: Mechanistic Insights and New Therapeutic Opportunities
Di Meco, A., Curtis, M. E., Lauretti, E., & Praticò, D. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.008 · Cited by 133
Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer’s disease
Ma, T., & Klann, E. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07506.x · Cited by 140
Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets
Vieira, M. N. N., Lima‐Filho, R. A. S., & Felice, F. G. D. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.014 · Cited by 133
Longevity and aging
Kaeberlein, M. (2013) · F1000Prime Reports · doi:10.12703/p5-5 · Cited by 112
Microglial mTOR Activation Upregulates Trem2 and Enhances β-Amyloid Plaque Clearance in the 5XFAD Alzheimer's Disease Model
Shi, Q., Chang, C., Saliba, A., & Bhat, M. A. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.2427-21.2022 · Cited by 139
Mitochondrial Quality Control via the PGC1α-TFEB Signaling Pathway Is Compromised by Parkin Q311X Mutation But Independently Restored by Rapamycin
Siddiqui, A., Bhaumik, D., Chinta, S. J., Rane, A., Rajagopalan, S., Lieu, C. A., Lithgow, G. J., & Andersen, J. K. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0109-15.2015 · Cited by 130
Protein misfolding disorders and macroautophagy
Menzies, F. M., Moreau, K., & Rubinsztein, D. C. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.10.010 · Cited by 129
Alborixin clears amyloid-β by inducing autophagy through PTEN-mediated inhibition of the AKT pathway
Wani, A., Gupta, M., Ahmad, M. N., Shah, A. M., Ahsan, A. U., Qazi, P. H., Malik, F. A., Singh, G., Sharma, P. R., Kaddoumi, A., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1596476 · Cited by 129
Consensus Paper: Pathological Mechanisms Underlying Neurodegeneration in Spinocerebellar Ataxias
Matilla‐Dueñas, A., Ashizawa, T., Brice, A., Magri, S., McFarland, K. N., Pandolfo, M., Pulst, S. M., Rieß, O., Rubinsztein, D. C., Schmidt, J., et al. (2013) · The Cerebellum · doi:10.1007/s12311-013-0539-y · Cited by 132
Micropublications: a semantic model for claims, evidence, arguments and annotations in biomedical communications
Clark, T., Ciccarese, P., & Goble, C. (2014) · Journal of Biomedical Semantics · doi:10.1186/2041-1480-5-28 · Cited by 149
Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
Kulkarni, A. S., Aleksić, S., Berger, D. M., Sierra, F., Kuchel, G. A., & Barzilai, N. (2022) · Aging Cell · doi:10.1111/acel.13596 · Cited by 132
Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives
Moreira, N. C. D. S., Lima, J. E. B. D. F., Marchiori, M. F., Carvalho, I., & Sakamoto‐Hojo, E. T. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210061 · Cited by 137
Drugs that modulate aging: the promising yet difficult path ahead
Kennedy, B. K., & Pennypacker, J. K. (2014) · Translational research · doi:10.1016/j.trsl.2013.11.007 · Cited by 127
Autophagy deregulation in neurodegenerative diseases – recent advances and future perspectives
Cheung, Z. H., & Ip, N. Y. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07314.x · Cited by 131
Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease
Wallin, A., Román, G. C., Esiri, M. M., Kettunen, P., Svensson, J., Paraskevas, G. P., & Kapaki, E. N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170803 · Cited by 133
Mitochondrial Dysfunction in Neural Injury
Zhao, X., Lu, M., Yuan, D., Xu, D.-E., Yao, P.-P., Ji, W., Chen, H., Liu, W., Yan, C.-X., Xia, Y., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00030 · Cited by 132
How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story
Richardson, A. G., Galván, V., Lin, A., & Oddo, S. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.12.002 · Cited by 122
Self-citation
and Alzheimer's disease
Brioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R., & Cowart, M. (2010) · Cited by 125
Cholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion
Barbero-Camps, E., Roca-Agujetas, V., Bartolessis, I., de Dios, C., Fernández-Checa, J. C., Marí, M., Morales, A., Hartmann, T., & Colell, A. (2018) · Autophagy · doi:10.1080/15548627.2018.1438807 · Cited by 125
Dual Role of Autophagy in Diseases of the Central Nervous System
Bar-Yosef, T., Damri, O., & Agam, G. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00196 · Cited by 128
The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy
Siman, R., Cocca, R., & Dong, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142340 · Cited by 122
Caloric restriction: Beneficial effects on brain aging and Alzheimer’s disease
Van Cauwenberghe, C., Vandendriessche, C., Libert, C., & Vandenbroucke, R. E. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9647-6 · Cited by 121
mTOR in Alzheimer disease and its earlier stages: Links to oxidative damage in the progression of this dementing disorder
Marzia Perluigi, A., Domenico, F. D., Barone, E., & Butterfield, D. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.04.025 · Cited by 126
mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse
Neasta, J., Barak, S., Hamida, S. B., & Ron, D. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12725 · Cited by 114
A Critical Kinase Cascade In Neurological Disorders: Pi3K, Akt and Mtor
Chong, Z. Z., Shang, Y., Wang, S., & Maiese, K. (2012) · Future Neurology · doi:10.2217/fnl.12.72 · Cited by 122
TOR on the brain
Garelick, M. G., & Kennedy, B. K. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.08.030 · Cited by 120
Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models
Domanskyi, A., Geißler, C., Vinnikov, I. A., Alter, H., Schober, A., Vogt, M. A., Gass, P., Parlato, R., & Schütz, G. (2011) · The FASEB Journal · doi:10.1096/fj.11-181958 · Cited by 121
Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity
Thellung, S., Corsaro, A., Nizzari, M., Barbieri, F., & Florio, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040901 · Cited by 118
Stress granule subtypes: an emerging link to neurodegeneration
Advani, V. M., & Ivanov, P. V. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03565-0 · Cited by 118
Deconstructing Mitochondrial Dysfunction in Alzheimer Disease
García‐Escudero, V., Martín-Maestro, P., Perry, G. L., & Ávila, J. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/162152 · Cited by 120
Rapamycin reduces severity of senile osteoporosis by activating osteocyte autophagy
Luo, D., Ren, H. J., Li, T., Lian, K., & Lin, D. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3325-5 · Cited by 114
Targeting disease through novel pathways of apoptosis and autophagy
Maiese, K., Chong, Z. Z., Shang, Y. C., & Wang, S. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.719499 · Cited by 150
Reversal of phenotypes of cellular senescence by pan-mTOR inhibition
Walters, H. E., Deneka-Hannemann, S., & Cox, L. S. (2016) · Aging · doi:10.18632/aging.100872 · Cited by 113
Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model
Steele, J., Lachenmayer, M. L., Ju, S., Stock, A., Liken, J., Kim, S. H., Delgado, L. M., Alfaro, I. E., Bernales, S., Verdile, G., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.106 · Cited by 115
Senescent Cells: A Therapeutic Target in Cardiovascular Diseases
Suda, M., Paul, K. H., Minamino, T., Miller, J. D., Lerman, A., Ellison, G. M., Tchkonia, T., & Kirkland, J. L. (2023) · Cells · doi:10.3390/cells12091296 · Cited by 119
dnc-1/dynactin 1 Knockdown Disrupts Transport of Autophagosomes and Induces Motor Neuron Degeneration
Ikenaka, K., Kawai, K., Katsuno, M., Huang, Z., Jiang, Y.-M., Iguchi, Y., Kobayashi, K. S., Kimata, T., Waza, M., Tanaka, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054511 · Cited by 122
Differential Activation of mTOR Complex 1 Signaling in Human Brain with Mild to Severe Alzheimer's Disease
Sun, Y.-X., Ji, X., Mao, X., Xie, L., Jia, J., Galván, V., Greenberg, D. A., & Jin, K. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-131124 · Cited by 119
Nutritional strategies to optimise cognitive function in the aging brain
Wahl, D., Cogger, V. C., Solon‐Biet, S. M., Waern, R. V. R., Gokarn, R., Pulpitel, T., de Cabo, R., Mattson, M. P., Raubenheimer, D., Simpson, S. J., et al. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.06.006 · Cited by 118
Autophagy–lysosomal-associated neuronal death in neurodegenerative disease
Nixon, R. A. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02799-7 · Cited by 126
Involvement of interleukin-1β in the autophagic process of microglia: relevance to Alzheimer’s disease
François, A., Terro, F., Janet, T., Bilan, A. R., Paccalin, M., & Page, G. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-151 · Cited by 92
Autophagy in neurodegenerative diseases: From pathogenic dysfunction to therapeutic modulation
Martínez‐Vicente, M. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.03.005 · Cited by 114
Microglial autophagy is impaired by prolonged exposure to β-amyloid peptides: evidence from experimental models and Alzheimer’s disease patients
Pomilio, C., Gorojod, R. M., Riudavets, M., Vinuesa, A., Presa, J., Gregosa, A., Bentivegna, M., Alaimo, A., Alcon, S. P., Sevlever, G., et al. (2020) · GeroScience · doi:10.1007/s11357-020-00161-9 · Cited by 109
Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade
Maiese, K., Chong, Z. Z., Wang, S., & Shang, Y. C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131113830 · Cited by 109
Milk—A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent Translation
Melnik, B. C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817048 · Cited by 108

Authors: Spilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V.
Affiliations: Buck Institute for Research on Aging (US)
The University of Texas at San Antonio Health Science Center (US)
University of California, San Francisco (US)
ORCID: Spilman, Patricia
Hart, Matthew J.
Debnath, Jayanta
Bredesen, Dale
Richardson, Arlan
Strong, Randy
Venue: PLoS ONE
Publisher: Public Library of Science (PLoS)
Published: 2010-04-01
Volume: 5
Issue: 4
Pages: e9979
ISSN: 1932-6203 (ISSN-L)
DOI: 10.1371/journal.pone.0009979
PMC: PMC2848616
OpenAlex: W2037653131
Cited by: 1,033
References: 52
Citations by year: 2026: 46 · 2025: 50 · 2024: 41 · 2023: 63 · 2022: 61 · 2021: 75 · 2020: 91 · 2019: 82 · 2018: 72 · 2017: 57 · 2016: 68 · 2015: 75 · 2014: 72 · 2013: 62 · 2012: 58
FWCI: 39.00
Type: journal article
Language: en
Update notices: correction (2011-12-27)
correction (2011-11-18)
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: PLoS ONE (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
eScholarship (California Digital Library) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders: U.S. Department of Veterans Affairs
Alzheimer's Association (NIRG-DDC-120433)
Buck Institute for Research on Aging
University of Texas Health Science Center at San Antonio
National Institute on Aging (P30AG13319, P30AG013319, U01AG022307)
National Cancer Institute (R01CA126792)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: rapamycin, mTOR inhibition, Alzheimer's disease, amyloid-beta 42, cognitive impairment, autophagy, lifespan extension, neuroprotection, therapeutic target
MeSH terms: Aging, Alzheimer Disease, Animals, Autophagy, Cognition Disorders, Disease Models, Animal, Immunosuppressive Agents, Signal Transduction, Amyloid beta-Peptides, Sirolimus, Mice, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks